Ian Clark Sells 14,180 Shares of Guardant Health (NASDAQ:GH) Stock

Guardant Health, Inc. (NASDAQ:GH) Director Ian Clark sold 14,180 shares of the company’s stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $158.92, for a total value of $2,253,485.60. Following the sale, the director directly owned 2,975 shares in the company, valued at approximately $472,787. This represents a 82.66% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Guardant Health Stock Up 2.1%

Shares of NASDAQ:GH traded up $3.39 on Wednesday, reaching $163.18. 2,396,847 shares of the company’s stock were exchanged, compared to its average volume of 2,323,223. Guardant Health, Inc. has a fifty-two week low of $43.66 and a fifty-two week high of $176.58. The business’s 50-day moving average is $145.04 and its two-hundred day moving average is $114.14. The firm has a market capitalization of $21.90 billion, a price-to-earnings ratio of -46.76 and a beta of 1.60.

Analyst Ratings Changes

Several equities analysts have recently commented on the company. Royal Bank Of Canada upped their target price on Guardant Health from $185.00 to $200.00 and gave the company an “outperform” rating in a report on Friday, July 31st. Sanford C. Bernstein boosted their price objective on Guardant Health from $175.00 to $200.00 and gave the company an “outperform” rating in a research report on Thursday, July 2nd. Wolfe Research assumed coverage on Guardant Health in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $150.00 price objective for the company. BTIG Research upped their price objective on Guardant Health from $190.00 to $195.00 and gave the stock a “buy” rating in a research note on Friday, July 31st. Finally, Bank of America increased their target price on Guardant Health from $135.00 to $190.00 and gave the stock a “buy” rating in a research report on Monday, July 6th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $183.78.

Hedge Funds Weigh In On Guardant Health

Hedge funds have recently made changes to their positions in the business. SWS Partners acquired a new stake in shares of Guardant Health during the 2nd quarter valued at $11,190,000. Handelsbanken Fonder AB increased its holdings in Guardant Health by 159.9% in the second quarter. Handelsbanken Fonder AB now owns 301,041 shares of the company’s stock worth $45,165,000 after buying an additional 185,200 shares during the last quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors bought a new stake in Guardant Health in the second quarter worth approximately $213,000. Allied Private Wealth LLC acquired a new position in shares of Guardant Health during the 2nd quarter worth $72,000. Finally, MRA Advisory Group lifted its stake in shares of Guardant Health by 6.2% in the 2nd quarter. MRA Advisory Group now owns 12,026 shares of the company’s stock valued at $1,804,000 after purchasing an additional 706 shares during the last quarter. Institutional investors and hedge funds own 92.60% of the company’s stock.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.